Denosumab Shows Safer Osteoporosis Control in PBC : Hepatology Communications | Nov 2025

Introduction

Primary Biliary Cholangitis is frequently complicated by osteoporosis due to chronic cholestasis, systemic inflammation, malabsorption and altered bone metabolism. Skeletal fragility substantially increases morbidity in PBC, yet evidence-based treatment strategies specific to this population remain limited.

Problem Statement

Although bisphosphonates are commonly used in cholestatic liver disease–associated osteoporosis, comparative prospective data evaluating newer antiresorptive therapies in patients with PBC are scarce.

Summary

The multicenter DELTA trial directly compared Denosumab with Zoledronic Acid in Japanese patients with PBC-associated osteoporosis.

This randomized open-label study demonstrated that denosumab achieved non-inferior improvement in lumbar spine bone mineral density compared with zoledronic acid over 12 months. Lumbar spine BMD increased substantially in both treatment groups, confirming the effectiveness of antiresorptive therapy in this high-risk population.

Notably, denosumab showed numerically greater improvement in total hip BMD, suggesting potentially stronger effects at cortical bone sites, although predefined statistical non-inferiority criteria were not fully met for this endpoint.

Both therapies significantly reduced bone turnover markers and improved biochemical indicators of bone remodeling, reflecting effective suppression of osteoclastic activity.

A particularly important finding was the superior tolerability profile of denosumab. Adverse events occurred substantially less frequently compared with zoledronic acid, highlighting a clinically meaningful safety advantage in patients with chronic liver disease who often have multiple comorbidities and frailty.

These results are highly relevant because osteoporosis management in PBC differs mechanistically from postmenopausal osteoporosis alone. Chronic cholestasis contributes to impaired osteoblast function, vitamin deficiencies, sarcopenia and altered calcium metabolism, creating a complex skeletal phenotype.

The study also reinforces the increasingly recognized burden of hepatic osteodystrophy in chronic cholestatic liver disease. Fractures in PBC are associated with significant functional decline, impaired quality of life and increased healthcare utilization.

From a practical standpoint, denosumab offers several advantages in PBC populations. Subcutaneous administration every six months may improve adherence compared with intravenous bisphosphonate strategies, particularly in older or frail patients.

The findings additionally raise important considerations regarding individualized bone management in chronic liver disease. Patients with renal dysfunction, gastrointestinal intolerance or poor bisphosphonate tolerance may particularly benefit from denosumab-based approaches.

Importantly, no major hepatic safety concerns emerged during the study. This is clinically reassuring given the frequent polypharmacy and metabolic vulnerability observed in advanced cholestatic disease.

The trial also underscores the need for proactive bone health surveillance in hepatology practice. Osteoporosis remains underdiagnosed and undertreated in PBC despite its major impact on long-term morbidity.

Broader implications extend beyond PBC alone. As survival improves across chronic liver diseases, management of extrahepatic complications including sarcopenia, frailty and osteoporosis is becoming increasingly central to comprehensive hepatology care.

Nevertheless, several limitations remain. The study was relatively small, limited to a Japanese population and evaluated surrogate bone density outcomes rather than fracture reduction.

Longer-term data regarding fracture prevention, durability of response and sequential treatment strategies following denosumab discontinuation will be important for future practice guidance.

Overall, the DELTA study supports denosumab as a safe and effective therapeutic option for osteoporosis in patients with PBC, demonstrating robust bone mineral density improvement alongside a favorable tolerability profile compared with zoledronic acid.